Ultragenyx Pharmaceutical Financials - Benzinga

Ultragenyx Pharmaceutical Inc

RARENASDAQ

Trade with Public

Trade with Public

$26.96

0.160.6%

At close: Aug 11, 5:00 PM EST

$26.90

-0.06-0.22%

After Hours: 4:09 PM EST

Earnings: Q2 2026 Earnings were released on Tue Aug 4th, after the market close

Conference Call: The most recent conference call started at 5:00 PM, 7 days ago

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Ultragenyx Pharmaceutical Financials

Ultragenyx Pharmaceutical (RARE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Ultragenyx Pharmaceutical Affirms FY2026 Sales Guidance of $730.000M-$760.000M vs $746.958M Est

Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2026 sales outlook from $730.000 million-$760.000 million to $730.000 million-$760.000 million vs $746.958 million estimate.

Benzinga Newsdesk

PRO
Ultragenyx Pharmaceutical Q2 EPS $(0.90) Beats $(1.51) Estimate, Sales $214.000M Beat $158.777M Estimate

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(1.51) by 40.4 percent. This is a 23.08 percent increase over losses of $(1.17) per

Benzinga Newsdesk

PRO
Ultragenyx Pharmaceutical Affirms FY2026 Sales Guidance of $730.000M-$760.000M vs $746.958M Est

Benzinga Newsdesk

PRO
Ultragenyx Pharmaceutical Q1 EPS $(1.84) Misses $(1.51) Estimate, Sales $136.000M Miss $158.777M Estimate

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

Why Is Ultragenyx Stock Sinking Friday?

Ultragenyx reports mixed Q4 earnings and initiates strategic restructuring plan to align resources with potential product launches.

Vandana Singh